Company Overview

Speclipse, Inc. has developed a transformative, patented technology for real-time, non-invasive, in-vivo cancer diagnosis utilizing laser spectroscopy and machining learning algorithms.

Clinical trials in the United States, Australia, and South Korea have shown a skin-cancer diagnostic accuracy rate of greater than 90%, higher than any other competing technologies that have attempted to achieve a similar clinical outcome. Diagnostic tools presently used by physicians such as dermascopes or confocal microscopes, provide 60-70% accuracy, far below that of Spectra-Scope®.

Speclispe, Inc. has acquired ISO134485 certification for its manufacturing facility, and Specta-Scope® is on-track, expected to obtain CE mark and TGA approval in early 2019.  

About Us

Speclipse was founded by three Stanford University graduates and a dermatologist in November 2015, and currently has offices in Silicon Valley, California and South Korea. Speclipse’s technology was first developed in conjunction with a South Korean national lab, KIMM (Korea Institute of Machinery and Materials), and Seoul National University Hospital. Speclipse raised $3M in November 2016 and is planning for commercial launch of their Spectra-Scope® product in 2019.



Core Technology

Speclipse's core diagnostic technology based on Laser Induced Plasma Spectroscopy (LIPS) and deep learning algorithms resides in "Spectra-Scope". It can be used by medical or cosmetic clinics who do not have existing laser equipment, or who prefer a small, portable stand-alone device for real-time diagnosis.

Due to the instantaneous nature and high-accuracy results provided by this technology, it is valuable for use in pathology labs for diagnosing biopsy samples, and beneficial for real-time diagnosis during oncological surgeries as well. 

Besides its outstanding clinical benefit, Spectra-Scope’s® size and portability make it uniquely qualified to address the unmet need for a technology which provides diagnostic accuracy and real-time results, with a cost-effective and minimal footprint.  



Core Members

Chief Executive Officer

Sung Hyun Pyun

  • Former Senior Engineer, KIMM

  • Former Consultant, The Boston Consulting Group

  • M.S. / Ph.D. in ME, Stanford University (Advanced Laser Diagnostics and Shock Tube Lab)  

  • B.S. in ME, KAIST

Chief Technology Officer

Wanki Min

  • M.S. in ME, Stanford University (Advanced Laser Diagnostics and Shock Tube Lab)  

  • B.S in ME, Seoul National University

  • Extensive experiences on laser sensor development

Chief AI Officer

Minsan Ko, PhD

  • Assistant professor of ICT dept., Hanyang University

  • Former data scientist at AIRI

  • Former data scientist at Samsung

  • M.S., Ph.D. in Computer Science, KAIST

Chief Medical Officer

Boncheol Goo

  • Head, Naeum Dermatology and Aesthetic Clinic

  • Medical Director, Lutronic, Inc.

  • M.D., Ph.D. in Yonsei Univ.

VP of US Business

Hyukmin Kwon

  • Former Lead Engineer, 1366 Technologies, Inc.

  • Ph.D. in ME, Massachusette Institute of Technology  (Varanasi Group)

  • M.S. in ME, Stanford University (Microfluidics Lab)  

  • B.S in ME, Seoul National University

Advisory Board

Medical Advisor

Chang Huh

  • Professor of Dermatology, SNU Hospital

  • M.D., Ph.D. in SNU

PD/FDA Process Advisor

Joe Mooney

  • Project Manger at Johnson & Johnson

  • 20+ year of FDA Class II device development

  • WPI M.S.

Investment Advisor

Jin Lee

  • President of Silicon Valley at LS Corp.

  • Former CTO at GE Healthcare

  • Ph.D. in ME, Stanford University



Korea Office

Markcity Orange #502

123, Unjung-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, Korea

US Office

310 De Guigne Dr
Sunnyvale, California 94085 USA

For any inquiries, 
Please call or e-mail us:


Copyright (C) 2015 Speclipse, Inc. All Rights Reserved